A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonist (VKA) for the prevention of stroke and non-central nervous system systemic embolism in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Trial Profile

A prospective, randomized, open-label, parallel-group, active-controlled, multicenter study exploring the efficacy and safety of once-daily oral rivaroxaban (BAY 59-7939) compared with that of dose-adjusted oral vitamin K antagonist (VKA) for the prevention of stroke and non-central nervous system systemic embolism in subjects with nonvalvular atrial fibrillation scheduled for cardioversion

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Rivaroxaban (Primary) ; Vitamin K antagonists
  • Indications Cardiovascular disorders; Stroke; Thromboembolism
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms X-VeRT
  • Sponsors Bayer
  • Most Recent Events

    • 30 Aug 2017 Results from an X-VeRT substudy presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology
    • 01 Sep 2015 According to a Janssen Pharmaceuticals media release, data from this study were published in the European Heart Journal.
    • 29 Aug 2014 According to a Janssen Research and Development media release, the findings of this trial will be presented at ESC Congress on September 2, 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top